Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN261201300031I
Award Date
9/20/13
Last Date to Order
4/17/17
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
5
Contract IDVs
Contract Awards
1
Transactions
5
Price Lists
Opportunity Stack
1
Federal Agency
National Cancer Institute
Awardee
Piramal Pharma Solutions Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Federal Contract Vehicle
Parenteral Dosage Forms for Clinical Studies
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Parenteral Dosage Forms for Clinical Studies
Master IDIQ
HHSN261201300031I
Indefinite Delivery Contract
1
Federal Contract Awards
Description
Update #1
Update #2
Update #3
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS FOR CLINICAL STUDIES; 9/20/2013-9/19/2018
Posted 9/20/13, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
4
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS FOR CLINICAL STUDIES; 9/20/2013-04/17/2017
Other Administrative Action
$0
4/14/17
3
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS FOR CLINICAL STUDIES; 9/20/2013-9/19/2018
Other Administrative Action
$0
1/9/14
2
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS FOR CLINICAL STUDIES; 9/20/2013-9/19/2018
Other Administrative Action
$0
1/2/14
1
THIS MODIFICATION REVISES ARTICLE G.1. ADDING AN ALTERNATIVE COR
Other Administrative Action
$0
11/12/13
Not listed
DEVELOPMENT AND PRODUCTION OF PARENTERAL DOSAGE FORMS FOR CLINICAL STUDIES; 9/20/2013-9/19/2018
Not listed
$0
9/20/13
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN261201300031I-HHSN26100001
DEVELOPMENT & PRODUCTION OF PARENTERAL DOSAGE FORMS FOR CLINICAL STUDIES; 09/20/2013-09/19/2018; TASK ORDER 1: KICK-OFF WEBINAR
Piramal Pharma Solutions Inc.
$1.0k
9/20/13
11/29/13
10/29/13
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
Development and Production of Parenteral Dosage Forms for Clinical Studies
Added: Apr 02, 2013 12:53 pm SYNOPSISN02CM37007-11"Development and Production of Parenteral Dosage Forms for Clinical Studies"The Development Therapeutics Program (DTP) of the National Cancer Institute (NCI) Division of Cancer Treatment and Diagnosis (DCTD) is soliciting organizations to develop and produce pharmaceutically acceptable parenteral dosage forms of promising new agents with activity against cancer. Certain agents selected by the NCI, DCTD will be as¬signed for development and production as parenteral products. Batch sizes shall range from small batches (100 - 200 units) to intermediate size batches to be used in Phase I and II trials (1,000 - 5,000 or more units). The capability to develop and manufacture other pharmaceutical dosage forms (i.e. sterile emulsions, liposomes and sterile micro-dispersions) is desirable.Data obtained from resulting contract(s) may 1) be used to support IND applications submitted by the National Cancer Institute to the U.S. Food and Drug Administration as well as foreign agen¬cies, 2) be provided to other NCI contractors engaged in large scale dosage form manufacture and analytical evaluation of these dosage forms and 3) be provided to physicians, pharmacists, nurses, and other medical personnel handling these products in a clinical setting.The contract type is multiple award, five (5) year, Indefinite Delivery Indefinite Quantity (IDIQ) type contracts. Task Orders will be either cost reimbursement completion or fixed price completion. Offerors will be invited to submit proposals for approximately 4 Development Task Orders and 4 Productions Task Orders as described in the Statement of Work (SOW). As discussed in the Statement of Work, offerors will need to demonstrate, at the time of proposal submission, that they have recent prior experience 1) manufacturing and delivering batches of pharmaceutical clinical product for human use, and 2) handling, developing, and manufacturing cytotoxic drugs.The NAICS code for this acquisition is 325412. The size standard for this NAICS Code is Number of Employees - 750. This acquisition will be a partial set aside.The solicitation is scheduled for electronic release on or about April 18, 2013. The RFP may be accessed through the NCI Office of Acquisitions, NCI homepage by using the following address: http://rcb.cancer.gov/rcb-internet/index.jsp; or through FedBizOpps.gov https://www.fbo.gov/. It is the offeror's responsibility to monitor the above internet sites for the release of this solicitation and amendments if any. ALL OFFERORS WILL BE RESONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. IN ADDITION, ALL QUESTIONS MUST BE SUBMITTED ELECTRONICALLY. NO FAX SUBMISSIONS WILL BE ACCEPTED. NO COLLECT CALLS WILL BE ACCEPTED.Point of Contact: Brenda Oberholzeroberholzerb@mail.nih.govRiverside Five, Suite 400, Room 40258490 Progress DriveFrederick, MD 21701Phone: 301-624-8750
N02CM37007-11
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
4/2/13, 12:53 PM